Thierry Abribat

Thierry Abribat has held various roles in the pharmaceutical industry throughout their career. In 1984, they started working as a Scientist at Sanofi until 1987. Thierry then worked at Université de Montréal as a Research Scientist from 1991 to 1996. In 1996, they co-founded Asana Laboratories and served as its President until 1999. From 1999 to 2005, they worked at Theratechnologies, first as Vice-President of Peptides and later as Executive Vice-President and Chief Scientific Officer. Thierry then served as the Chief Operating Officer and Acting Vice-President of R&D at OPi SA Pharmaceuticals for Rare Diseases from 2005 to 2007. In the same year, they founded TAB Consulting and served as its Manager. In 2007, they founded Alizé Pharma and served as its CEO until 2017. Thierry also founded Alizé Pharma 2 in 2008 and served as its CEO until 2016. From 2017 to 2018, they were a Member of the Board of Directors at Millendo Therapeutics. Finally, in 2015, they founded and became the CEO of Amolyt Pharma, formerly known as Alizé Pharma, which focuses on rare endocrine and metabolic diseases.

Thierry Abribat has a rich educational background in various fields. In 1987, they earned a degree in Genetics and Cellular Biology from Institut Pasteur. Later on, in 1988, they completed their Doctorate in Veterinary Medicine at Ecole Nationale Vétérinaire de Toulouse. Building upon their veterinary expertise, Thierry pursued a PhD in Neuroendocrinology at Toulouse INP, starting in 1991. Continuing their educational journey, they attended McGill University in 1996, where they completed an Executive Development Course, enhancing their knowledge and skills in executive-level management.